2,749 reports of this reaction
3.0% of all RANITIDINE HYDROCHLORIDE reports
#7 most reported adverse reaction
NEOPLASM MALIGNANT is the #7 most commonly reported adverse reaction for RANITIDINE HYDROCHLORIDE, manufactured by WinCo Foods, LLC. There are 2,749 FDA adverse event reports linking RANITIDINE HYDROCHLORIDE to NEOPLASM MALIGNANT. This represents approximately 3.0% of all 90,318 adverse event reports for this drug.
RANITIDINE HYDROCHLORIDE has an overall safety score of 95 out of 100. Patients taking RANITIDINE HYDROCHLORIDE who experience neoplasm malignant should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEOPLASM MALIGNANT is a less commonly reported adverse event for RANITIDINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to neoplasm malignant, the following adverse reactions have been reported for RANITIDINE HYDROCHLORIDE:
The following drugs have also been linked to neoplasm malignant in FDA adverse event reports:
NEOPLASM MALIGNANT has been reported as an adverse event in 2,749 FDA reports for RANITIDINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEOPLASM MALIGNANT accounts for approximately 3.0% of all adverse event reports for RANITIDINE HYDROCHLORIDE, making it a notable side effect.
If you experience neoplasm malignant while taking RANITIDINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.